No active 13F manager changed its position in Faeth Therapeutics, Inc. last quarter. Over the last 180 days, 3 insiders bought and 3 insiders sold, a net +$825K in open-market trades.
The legs disagree, or only one of them leans.
Not held in any tracked 13F filing yet.
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jul 1, 2026 | Stephenson Brian C | Chief Financial Officer | Buy (P) 2 lots, same day | 5K | $117K |
| Jun 30, 2026 | Stephenson Brian C | Chief Financial Officer | Buy (P) 3 lots, same day | 8K | $189K |
| Jun 29, 2026 | Stephenson Brian C | Chief Financial Officer | Buy (P) | 831 | $19K |
| Jun 26, 2026 | Stephenson Brian C | Chief Financial Officer | Buy (P) 4 lots, same day | 6K | $156K |
| Jun 24, 2026 | Stephenson Brian C | Chief Financial Officer | Buy (P) 4 lots, same day | 9K | $245K |
| Jun 23, 2026 | Stephenson Brian C | Chief Financial Officer | Buy (P) 3 lots, same day | 9K | $225K |
| Jun 22, 2026 | Stephenson Brian C | Chief Financial Officer | Buy (P) 5 lots, same day | 8K | $181K |
| Jun 22, 2026 | Parikh Anand Kiran | President and CEO, Director | Buy (P) | 3K | $55K |
| Jun 1, 2026 | Cambrian BioPharma Inc | 10% Owner | Sell (S) 2 lots, same day | 25K | $501K |
| Jun 1, 2026 | Peyer James | 10% Owner | Sell (S) 2 lots, same day | 25K | $501K |
| Apr 7, 2026 | Millennium Management Llc | 10% Owner | Sell (S) 5 lots, same day | 8K | $253K |
| Apr 7, 2026 | Millennium Management Llc | 10% Owner | Buy (P) | 1K | $37K |
One row per insider, day and transaction code; shares and value are summed across the lots. Every lot is on the full insider page and in the filing.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 0 | 0 | – |
Insiders Form 4 open-market | 3 | 3 | +$825K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for Faeth Therapeutics, Inc.
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/FTH/capital-change-brief"
Use Arkolith's capital_change_brief for Faeth Therapeutics, Inc.. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + the live filing stream, joined for FTH. Filings are public domain, sourced to SEC EDGAR.